| URL: | https://unsw-data-analytics.shinyapps.io/COVID_CombTherap/ |
| Full name: | |
| Description: | COVID-CDR enables a visual and quantitative investigation of the interplay between the primary drug targets and the SARS-CoV-2-host interactome in the human protein-protein interaction network. |
| Year founded: | 2021 |
| Last update: | |
| Version: | |
| Accessibility: |
Accessible
|
| Country/Region: | Saudi Arabia |
| Data type: | |
| Data object: | |
| Database category: | |
| Major species: | |
| Keywords: |
| University/Institution: | Imam Mohammad Ibn Saud Islamic University (IMSIU) |
| Address: | Advanced Data and Network Science Lab, Department of Mathematics & Statistics, Faculty of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 13318, Saudi Arabia |
| City: | Riyad |
| Province/State: | Riyadh |
| Country/Region: | Saudi Arabia |
| Contact name (PI/Team): | AKM Azad |
| Contact email (PI/Helpdesk): | savilbd@gmail.com |
|
Integrative resource for network-based investigation of COVID-19 combinatorial drug repositioning and mechanism of action. [PMID: 34278363]
An effective monotherapy to target the complex and multifactorial pathology of SARS-CoV-2 infection poses a challenge to drug repositioning, which can be improved by combination therapy. We developed an online network pharmacology-based drug repositioning platform, COVID-CDR (http://vafaeelab.com/COVID19repositioning.html), that enables a visual and quantitative investigation of the interplay between the primary drug targets and the SARS-CoV-2-host interactome in the human protein-protein interaction network. COVID-CDR prioritizes drug combinations with potential to act synergistically through different, yet potentially complementary, pathways. It provides the options for understanding multi-evidence drug-pair similarity scores along with several other relevant information on individual drugs or drug pairs. Overall, COVID-CDR is a first-of-its-kind online platform that provides a systematic approach for pre-clinical investigation of combination therapies for treating COVID-19 at the fingertips of the clinicians and researchers. |